EPA to Ban Last Form Of Asbestos Used in US EPA to Ban Last Form Of Asbestos Used in US
The U.S. Environmental Protection Agency on Monday finalized a rule that would ban using and importing cancer-causing asbestos, a material still used in some vehicles and in...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 18, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

FDA Approves First CAR T-Cell Therapy for rrCLL, rrSLL FDA Approves First CAR T-Cell Therapy for rrCLL, rrSLL
The accelerated approval for liso-cel was based on findings showing 20% of patients achieved a complete response from a one-time infusion after at least two prior lines of therapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Customized Radiation of Uterus May Not Compromise Outcomes Customized Radiation of Uterus May Not Compromise Outcomes
Researchers found that patients with locally advanced cervical cancer who received less than whole uterus irradiation had low local recurrence rates and fewer side effects.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Gilead CAR-T Cancer Therapy Capacity to Quadruple by 2026 Gilead CAR-T Cancer Therapy Capacity to Quadruple by 2026
Gilead Sciences will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the U.S. biotech ' s manufacturing processes, an...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

FDA Approves New Esophageal Cancer Drug FDA Approves New Esophageal Cancer Drug
The checkpoint inhibitor is approved for second-line treatment of patients with esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-L1 inhibitor.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 15, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Geron's Blood Disorder Drug Gets FDA Advisers' Backing Geron's Blood Disorder Drug Gets FDA Advisers' Backing
Advisers to the U.S. Food and Drug Administration on Thursday backed benefits of Geron ' s blood disorder drug, saying it outweighed the risks associated with the treatment,...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 14, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

In Memoriam: Drs Worta McCaskill-Stevens and Edith Mitchell In Memoriam: Drs Worta McCaskill-Stevens and Edith Mitchell
Dr Kathy Miller remembers two influential women in the breast cancer field, Dr Worta McCaskill-Stevens and Dr Edith Mitchell.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 14, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

No Benefit to Adding Chemotherapy in Older Adults With NSCLC No Benefit to Adding Chemotherapy in Older Adults With NSCLC
Adding chemotherapy to immunotherapy increased the adverse event burden without improving survival outcomes compared with immunotherapy alone in older adults with NSCLC.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 14, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Consider These Factors in a Radiation Oncology Position Consider These Factors in a Radiation Oncology Position
Before accepting a position at an academic radiation oncology practice, a prospective employee should evaluate three main features of the job — compensation, daily duties, and location.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 13, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Merck to Test Single-dose Regimen Of HPV Vaccine Gardasil 9 Merck to Test Single-dose Regimen Of HPV Vaccine Gardasil 9
Merck& Co said on Wednesday it plans to conduct clinical trials testing its human papillomavirus (HPV) vaccine Gardasil 9 to evaluate the efficacy and safety of a...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 13, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

NordICC Controversies: Practice Differences in Europe and the US NordICC Controversies: Practice Differences in Europe and the US
Mark A. Lewis, MD, discusses salient differences between the Northern European practices that were studied in NordICC and the American population.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 12, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Adjuvant IO: Survival Advantage'Big News' in Renal Cancer Adjuvant IO: Survival Advantage'Big News' in Renal Cancer
A 40% reduced risk for death from renal cancer, as reported by KEYNOTE-564, tops Dr Brian Rini ' s list of takeaways from ASCO GU 2024. Also discussed are updates on doublet therapy in advanced disease.Medscape (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 12, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

New Data: How Early Colon Cancer Cells Evade Immune System New Data: How Early Colon Cancer Cells Evade Immune System
A new study reveals how early colorectal cancer cells may hide from the immune system, building on growing and crucial research on cancer immune evasion.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 12, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

After SABR, 100% Local Control at 1 Year in Kidney Cancer After SABR, 100% Local Control at 1 Year in Kidney Cancer
Among patients with primary RCC who did not undergo surgery, SABR led to no local treatment failures at 1 year, new phase 2 data showed.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 12, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

FTC, 10 US States Sue'sham' Women's Cancer Charity FTC, 10 US States Sue'sham' Women's Cancer Charity
The Federal Trade Commission and 10 U.S. states on Monday sued what they called a " sham " charity that raised $18.25 million to help women fight cancer, but spent just...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 11, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news